Pharming Group N.V annual net profit margin
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Net Profit Margin Growth & History (PHAR)
Pharming Group N.V's net profit margin was 0.67% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 0.67% | +4.66 pp |
| 2024 | 2024-12-31 | −3.98% | +0.32 pp |
| 2023 | 2023-12-31 | −4.30% | −10.95 pp |
| 2022 | 2022-12-31 | 6.65% | −1.39 pp |
| 2021 | 2021-12-31 | 8.04% | −9.75 pp |
| 2020 | 2020-12-31 | 17.79% | −3.62 pp |
| 2019 | 2019-12-31 | 21.41% | — |
Pharming Group N.V quarterly net profit margin
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.82% | −3.22 pp |
| Q1 2026 | 2026-03-31 | −7.20% | — |
| Q4 2025 | 2025-12-31 | 4.98% | — |
| Q3 2025 | 2025-09-30 | 7.76% | — |
| Q2 2025 | 2025-06-30 | 5.04% | — |
Pharming Group N.V net profit margin trends
Over the last five fiscal years, Pharming Group N.V's net profit margin decreased from 17.79% to 0.67%, a change of −17.12 percentage points. The latest reported quarter, Q2 2026, shows 1.82%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...